The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemias
Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses strategies to treat pediatric FLT3-mutant acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Pre-clinical studies investigating gilteritinib, a FLT3 inhibitor, have demonstrated that combining gilteritinib and chimeric antigen receptor (CAR) T-cell therapy was effective in the aforementioned patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
